#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic hepatitis B Philadelphia positive acute lymphocytic leukaemia Albright's disease Glomerulonephritis Myotonic dystrophy Toxic epidermal necrolysis Breast cancer Cholangiocarcinoma Systemic scleroderma Haemophilia B without inhibitors Neutropenia Non-Hodgkin's lymphoma unspecified histology indolent Osteosarcoma Liposarcoma recurrent Penile cancer More trials…

    Learn about Rare Diseases

    Acute respiratory distress syndrome – Treatment Epidermolysis bullosa – Basic Information Glycogen storage disease type II – Trials in Disease Mantle cell lymphoma stage II – Diagnostics Leiomyosarcoma recurrent – Diagnostics Hereditary ataxia – Diagnostics Paroxysmal nocturnal haemoglobinuria – Basic Information Small intestine leiomyosarcoma – Diagnostics Angiosarcoma – Diagnostics MELAS syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Indacaterol Maleate Citric Acid Monohydrate Ag13909 METAMIZOLE SODIUM Star-0215 Ferric Derisomaltose Capmatinib Kd050 Human Apotransferrin Kpl-404 Prednisolone Redasemtide Glycerol Ioversol Vanzacaftor TROFOLASTAT Dermatophagoides Farinae ALLO-QUADCAR01-T Itraconazole Atomoxetine More therapies…

    Learn about Your Condition

    Arterial stiffness Rectal neoplasm Facial paresis Biliary adenoma Coronary artery occlusion Neuroblastoma Keratosis follicular Tardive dyskinesia Alpha-1 antitrypsin deficiency Vertigo Thrombosis Migraine with aura Malignant melanoma of eyelid Hereditary ataxia Liver transplant More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut de Cancérologie Hématologie Universitaire…

Institut de Cancérologie Hématologie Universitaire de Saint Etienne (iCHUSE)

Avenue Albert Raimond, Saint Priest En Jarez, 42270, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Deep vein thrombosis
    • Thrombolysis
    Investigated Drugs:
    • Bay 3018250
    Belgium Bulgaria Czechia France Germany Greece +5

  • Study on Managing Moderate Postoperative Recurrence in Crohn’s Disease with Infliximab for Patients After Ileocolonic Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Infliximab
    Belgium France Spain

  • Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Aprepitant
    • Netupitant
    • Ondansetron
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Azathioprine
    • Jnj-77242113
    • Mercaptopurine
    Belgium Czechia France Germany Hungary Italy +3

  • Study on Long-Term Safety of Atogepant for Preventing Migraine in Patients with Chronic or Episodic Migraine

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Atogepant
    Czechia Denmark France Germany Hungary Italy +3

  • Study on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Cyclophosphamide
    • Doxorubicin
    • Lenalidomide
    Belgium France

  • Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Anal squamous cell carcinoma
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Docetaxel
    France

  • Study on Sibeprenlimab for Patients with IgA Nephropathy

    Not recruiting

    3 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Sibeprenlimab
    Belgium Croatia Czechia France Germany Greece +6

  • Study Comparing Balloon with Oxytocin and Oral Misoprostol for Inducing Labor in First-Time Mothers with Premature Rupture of Membranes at Term

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Premature rupture of membranes
    Investigated Drugs:
    • Amoxicillin
    • Amoxicillin Sodium
    • Clindamycin
    France

  • Study on Adding Ipilimumab to Atezolizumab and Bevacizumab for Patients with Liver Cancer Receiving First-Line Treatment

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Hepatic cancer
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    • Ipilimumab
    France
Previous Page
1 … 40 41 42 43 44 … 46
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!